Navigation Links
Palatin Technologies Reports Successful Completion Of Device Bioequivalence Trial
Date:10/28/2013

CRANBURY, N.J., Oct. 28, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today announced the successful completion of a clinical trial designed to demonstrate equivalence of subcutaneously administered bremelanotide via autoinjector compared to pre-filled syringe administration. Bioequivalence was achieved in this clinical trial. Palatin used pre-filled syringes in its Phase 2 clinical trials, but will use the single-dose disposable autoinjector in its planned Phase 3 clinical trials and for commercialization.

Stephen T. Wills, Chief Operating Officer and Chief Financial Officer of Palatin Technologies, commented, "Demonstrating bioequivalence in this study allows us to move forward with confidence regarding the delivery of bremelanotide via autoinjector. The pharmacokinetic profile of bremelanotide using the autoinjector device was consistent with the pharmacokinetic data collected in our completed positive Phase 2B study which used pre-filled syringes. The single-dose disposable autoinjector provides patients with a safe, easy to use device for the delivery of bremelanotide."

The design was a single-center, randomized, double-blind (to device administration) study in 36 healthy female subjects to determine the bioequivalence of 1.75 mg of bremelanotide administered by two different devices. There were no serious adverse events reported and there were no discontinuations in the study.

About Female Sexual Dysfunction
Female Sexual Dysfunction (FSD) covers multi-factorial conditions that have anatomical, physiological, medical, psychological and social components. FSD includes four categories: Sexual Desire Disorders (hypoactive sexual desire disorder [HSDD], sexual aversion disorder), Female Sexual Arousal Disorder (FSAD), Female Orgasmic Disorder (FOD), and Sexual Pain Disorders (dyspareunia, vaginismus). To establish a diagnosis of FSD, one or more of these disorders must be associated with personal distress, as determined by the affected women. In the 2006 PRESIDE study (Prevalence of Female Sexual Problems Associated with Distress and Determinants of Treatment Seeking, reference: Obstet Gynecol 2008 Nov; 112(5):970-8), Shifren and colleagues studied over 30,000 US women, reporting an age-adjusted point prevalence of sexual difficulties causing personal distress in 12% of respondents.

There are no drugs in the United States approved for the treatment of FSD.  Bremelanotide is an on-demand treatment for FSD with the potential to transform the treatment of patients with FSD.

Bremelanotide for Female Sexual Dysfunction
Palatin is developing subcutaneously administered bremelanotide for the treatment of FSD in premenopausal women diagnosed with FSD. Bremelanotide, which is a melanocortin agonist (a compound which binds to a cell receptor and triggers a response) drug candidate, is a synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone).

About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at http://www.palatin.com


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Palatin Technologies Announces Last Patient Completed Treatment In Phase 2B Bremelanotide Female Sexual Dysfunction Trial
2. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific Peptides
3. Palatin Technologies, Inc. To Report Fiscal Year 2013 Fourth Quarter Results
4. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2013 Results
5. West Physics Consulting Teams with Mirion Technologies Dosimetry Services Division to Deliver Radiation Detection Services
6. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
7. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
8. BioSpecifics Technologies Corp. Announces Rescheduled First Quarter 2012 Financial Results Conference Call to May 10, 2012
9. Global Ablation Technologies Market worth $12.4 Billion by 2016: MarketsandMarkets
10. ICU Medical, Inc. Plans to "Vigorously Seek to Collect Damages" in wake of Patent Infringement Victory Over RyMed Technologies
11. BioStorage Technologies to Lead Discussion on the Value of a Comprehensive Sample Management Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ISELIN, New Jersey , April 29, 2016 ... Omnichannel Software Suite for Life Sciences, Product Development ... and Global Life Science Customer Base . ... healthcare solutions provider, today announced the acquisition of ... is a global leader in adaptive sales enablement ...
(Date:4/29/2016)... India , April 29, 2016 ... the life science laboratory due to the growing demands ... by advance technology, contemporary automated systems are already adept ... performed by slow, tedious and manual labor. Instrumentation continues ... were not even conceivable just a few years ago. ...
(Date:4/28/2016)... DUBLIN , April 28, 2016 ... the "Global Plastic Surgery Products Market 2016-2020" ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , The global plastic ... CAGR of 9.47% during the period 2016-2020. , ,The ... factor leading to the growth of the market. Lasers ...
Breaking Medicine Technology:
(Date:5/2/2016)... ... May 02, 2016 , ... Summit BHC (Summit), a leading ... Twin Lakes Recovery Center. Located east of Atlanta in Monroe, Georgia, the ... residential facility is set on 34 acres of beautiful, secluded property that will ...
(Date:5/1/2016)... ... May 02, 2016 , ... Avid collector, Andrew Hawley from ... Pavilion in Columbia, Maryland concert posters. Dail Beeghley hit a poster design achievement ... August 16. According to Hawley, “The Pavilion was built to host the National ...
(Date:5/1/2016)... , ... May 01, 2016 , ... Outdoor Growing Bans ... marijuana industry, has put the law in the hands of the local communities ... 1, 2016, California voted to allow counties to vote on growing regulations by 3/1/2016 ...
(Date:4/30/2016)... ... 2016 , ... Powerful tools of hypnosis, hypnotherapy and ... What is hypnosis and hypnotherapy and why after centuries, it is now scientifically ... and acute), birthing processes and medical procedures, depression, anxiety, fear reactions, anxiety attacks, ...
(Date:4/30/2016)... ... April 30, 2016 , ... A ... use of the HyProCure sinus tarsi implant. ( http://www.cbc.ca/news/canada/ottawa/banned-quebec-dentist-pierre-dupont-working-as-chiropodist-in-ottawa-1.3515494 ) The ... minimally invasive procedure performed, when indicated, to correct the partial displacement of ...
Breaking Medicine News(10 mins):